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Background: The NDF-RT (National Drug File Reference Terminology) is an ontology, which describes drugs and
their properties and supports computerized physician order entry systems. NDF-RT’s classes are mostly specified
using only necessary conditions and lack sufficient conditions, making its use limited until recently, when asserted
drug-class relations were added. The addition of these asserted drug-class relations presents an opportunity to
compare them with drug-class relations that can be inferred using the properties of drugs and drug classes in NDF-RT.
Methods: We enriched NDF-RT’s drug-classes with sufficient conditions, added property equivalences, and then used
an OWL reasoner to infer drug-class membership relations. We compared the inferred class relations to the recently
added asserted relations derived from FDA Structured Product Labels.
Results: The inferred and asserted relations only match in about 50% of the cases, due to incompleteness of the drug
descriptions and quality issues in the class definitions.
Conclusions: This investigation quantifies and categorizes the disparities between asserted and inferred drug-class
relations and illustrates issues with class definitions and drug descriptions. In addition, it serves as an example of the
benefits DL can add to ontology development and evaluation.
Keywords: Ontology, Description logics, Quality assurance, National drug file-reference terminologyIntroduction
We rely on ontologies throughout biomedicine, from the
life sciences to the clinic [1]. As Electronic Health
Record adoption increases in the clinic, so too will the
reliance on the ontologies that facilitate their meaningful
use. Clinical decision support and analytics are functions
supported by ontologies. For example, computerized
physician order entry (CPOE) systems typically leverage
drug ontologies to ensure that patients are safely
prescribed drugs in accordance with clinical guidelines
(e.g., [2]).
An example of such an ontology is the National Drug
File-Reference Terminology (NDF-RT), an extension to
the drug formulary used by the Veterans Administration
and developed using a description logics (DL) formalism.* Correspondence: olivier@nlm.nih.gov
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unless otherwise stated.It provides a rich description of pharmacologic classes in
reference to properties, such as mechanism of action,
physiologic effect, chemical structure and therapeutic
intent. NDF-RT can be leveraged to prevent a patient
allergic to penicillin drugs from being prescribed amoxi-
cillin, a penicillin antibacterial.
However, NDF-RT only specifies necessary conditions
for class membership to the pharmacologic classes, but
not sufficient conditions. (In DL parlance, these classes
are “primitive”, not defined.) As a consequence, a DL
reasoner is unable to classify automatically drugs as
members of a given pharmacologic class, even when
both drugs and pharmacologic classes are described in
terms of the same properties. The inability to classify
drugs into their classes limits the usefulness of NDF-RT
in systems like CPOE that rely on such information.
In previous work, where we overcame this limitation
by augmenting the pharmacologic classes with necessary
and sufficient conditions, we found that we could inferntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ally, we demonstrated the use of a modified version of
NDF-RT for clinical decision purposes (patient classifica-
tion). One limitation of this work was that we did not
evaluate the inferred drug-class membership relations
beyond our proof-of-concept application.
NDF-RT recently integrated authoritative drug-class
membership assertions extracted from the Structured
Product Labels (package inserts) by the Food and Drug
Administration (FDA), along with a specification of the
drugs in terms of the same properties used for specifying
the classes. These assertions remove the drug-class
membership limitation we highlighted earlier, instead
providing explicit drug-class membership relations that
do not rely on DL reasoning. But precisely because these
asserted drug-class relations have been made independ-
ently of the logical definitions of the classes, there is the
possibility for the asserted and inferred drug-class mem-
bership relations to be inconsistent.
The objective of this work is to evaluate the consistency
of the drug-class membership relations that were inferred
from the pharmacologic class definitions and drug
descriptions, against the newly asserted, authoritative
drug-class membership relations. This evaluation is also
an indirect contribution to the assessment of the class def-
initions and the drug descriptions in terms of complete-
ness and consistency (i.e., agreement between information
sources).
Background
NDF-RT drugs and classes
The National Drug File Reference Terminology (NDF-
RT) is a resource developed by the Department of
Veterans Affairs (VA), Veterans Health Administration,
as an extension of the VA National Drug File [4]. Like
other modern biomedical terminologies, NDF-RT is de-
veloped using description logics and is available in native
XML format. The version used in this study is the latest
version available, dated November 3, 2014, downloaded
from [5], from which we derived our augmented
representation.
This version covers 7,287 active moieties (DRUG_
KIND, level = ingredient), as well as 543 Established
Pharmacologic Classes (EPCs) specified in reference to
some of the properties of the active moieties. NDF-RT
now contains several sources of relations between drugs
and their properties. The April 2014 version of NDF-RT
introduced a new set of relations between drugs and
their properties originating from the class indexing file
released as part of DailyMed, identified by the suffix
“FDASPL”. Moreover, this version also introduced au-
thoritative drug-class membership assertions from the
same source. Finally, NDF-RT also provides a specifica-
tion of the EPCs in reference to the same propertiesused for describing the drugs themselves, provided by
“Federal Medication Terminologies subject matter ex-
perts” and identified by the suffix “FMTSME”. In this
work, we focus on the drug-property assertions from
FDASPL, class-property assertions from FMTSME, and
drug-class assertions provided by the FDA.
Description logics
In short, Description Logics (DL) are a set of logical
constructs with which one can develop ontologies.
Krötzsch and colleagues provide a more formal intro-
duction to DL [6]. Like other knowledge representation
methods, DL allows one to specify, in a computable
fashion, the entities (i.e., classes) that exist in a given do-
main and the relationships (i.e., relations) between them.
In comparison to older methods of knowledge represen-
tation, DL ensures common, unambiguous semantics so
that the ontology’s interpretation is consistent across
software and users. This consistent logical underpinning
enables the use of reasoners, which are programs that
compute (i.e., infer) the logical entailments (i.e., conclu-
sions) of a given ontology. For example, if Alprostadil
has physiologic effect Venous dilation and Venous dila-
tion is-a Vasodilation, a reasoner concludes that Alpros-
tadil has physiologic effect Vasodilation. A typical
approach to developing ontologies with DL is to specify
a set of properties that each class has (e.g., Penicillin
antibacterial has ingredient Penicillin and treats or pre-
vents Bacterial infection; Antiseptic treats or prevents
Bacterial infection) and then infer the additional rela-
tions among classes. With a set of specified classes, a
reasoner can then classify them into an inferred hier-
archy. In our example, the inferred hierarchy would
show that Penicillin antibacterial is-a Antiseptic. In the
context of this study, NDF-RT uses this same approach,
specifying EPCs in terms of their properties. Unlike the
example above, however, pharmacologic classes in NDF-
RT (EPCs) are “primitive”, in that they only specify the
necessary conditions of class membership, and therefore
prevent a reasoner from constructing a useful inferred
hierarchy. Later, we describe how we enrich NDF-RT
with sufficient conditions so that we can take full advan-
tage of a reasoner.
In this work, we use OWL, the web ontology language,
a web standard for developing ontologies that leverages
DL. OWL is the de facto standard for biomedical ontol-
ogies and there is a suite of tools for developing OWL
ontologies, including development environments such as
Protégé [7] and reasoners such as HermiT [8].
Related work
In addition to being used as a framework for building on-
tologies, DL has been shown to be useful for reasoning
with biomedical entities, including protein phosphatases
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ledge, DL reasoning has not yet been applied to the auto-
matic classification of drugs, except for our previous work
on anti-coagulants [3].
NDF-RT is used frequently as a resource for standard-
izing pharmacologic classes (e.g., [11,12]). However, in-
vestigators generally use the drug properties as classes
(e.g., drugs that have the physiologic effect “decreased co-
agulation activity” for anti-coagulants), rather than the
EPCs. Moreover, only asserted relations are used in most
investigations, as opposed to inferred drug-class relations.
The specific contribution of this paper is the augmen-
tation of the logical definitions of pharmacologic classes
in NDF-RT to enable the automatic inference of drug-
class membership relations using a DL reasoner. We
substantially extend our previous work on anticoagu-
lants, by generalizing it to all pharmacologic classes and
providing a comparison to authoritative, asserted drug-
class relations from the FDA.
Methods
Our approach to evaluating inferred drug-class member-
ship relations in NDF-RT is summarized as follows.
First, we converted the NDF-RT data from their original
format (XML) to a DL format (OWL). This conversion
process augments the EPCs with necessary and sufficient
conditions. These conditions allowed a DL reasoner to
classify drugs into their respective classes using the class
definitions and the properties of drugs. We created two
OWL datasets. One, used as a gold standard, only con-
tains the asserted, authoritative drug-class relations. In
contrast, these asserted relations have been removed
from the second dataset, so that only inferred drug-class
relations were present after the reasoner runs (i.e., in-
ferred by the reasoner). We ran a DL reasoner and then
compared inferred and asserted drug-class relations
from the perspective of drugs and from that of classes.
In order to restrict this investigation to clinically sig-
nificant drugs, we mapped all NDF-RT ingredients to
RxNorm and required that ingredients be linked to clin-
ical drugs. We further normalized all ingredients to base
ingredients in RxNorm, to abstract away from minor dif-
ferences in ingredients, including salts, esters and com-
plexes, which rarely affect drug-class membership. In
practice, we mapped the “precise ingredients” in RxNorm
(e.g., albuterol sulfate) to their base ingredient (albuterol).
Multi-ingredient drugs were ignored, because there is
often more variability in their classification.
Augmenting pharmacologic classes with sufficient
conditions
In order to produce the two OWL datasets used for
comparing asserted and inferred drug-class relations, we
started by creating a “baseline” OWL representationfrom the original XML dataset, which we used as our
asserted dataset (dataset “A”). Next, as previously de-
scribed in [3], we transformed the primitive EPCs into
defined classes by taking the existing set of properties
for each class (i.e., necessary conditions) and using them
to “define” the class. In particular, all properties are
folded into a single owl:equivalentClass (≡)
axiom, thereby specifying necessary and sufficient condi-
tions of each class. For the purpose of this work, we
focus on the three main properties used for the descrip-
tion of the drugs (mechanism of action, physiologic
effect and chemical structure). Additionally, we lever-
aged the therapeutic intent relations (may_treat and
may_prevent) present in NDF-RT, because many EPCs
refer to them in their definitions. These relations link
drugs and EPCs to disease entities.
We further modified this OWL file by applying a series
of transformations that are necessary for enabling proper
inference (dataset “I”). We harmonized the names of
roles used in the definition of the classes (e.g., has_
MoA_FMTSME) with those used in the description of
the drugs (e.g., has_MoA_FDASPL) by creating owl:
equivalentProperty axioms between them. The
following equivalences are created:
 has_MoA_FMTSME ≡ has_MoA_FDASPL (for
mechanism of action),




 may_treat_FMTSME ≡may_treat_NDFRT, and
 may_prevent_FMTSME ≡may_prevent_NDFRT.
Inferring relations between drugs and EPCs
Next, we leveraged an OWL reasoner to infer the drug-
class membership relations from the class definitions
and the descriptions of drugs. Using the necessary and
sufficient conditions we created for the classes, an OWL
reasoner infers a subclass relation between a drug and a
pharmacologic class when the properties of the drug and
those of the pharmacologic class are shared. For ex-
ample, the class beta2-Adrenergic Agonist [EPC]
(N0000175779) is defined as equivalent to ('Pharmaceut-
ical Preparations' and (has_MoA_FMTSME some
'Adrenergic beta2-Agonists [MoA]')). The drug albuterol
(N0000147099) has the property has_MoA_FDASPL
some 'Adrenergic beta2-Agonists [MoA]', and is therefore
inferred as being a subclass of beta2-Adrenergic Agonist
[EPC]. (The inference will also occur if the property of
the drug is a subclass of the property used in the defin-
ition of the class). Figure 1 provides a schematic of the
above example.
Figure 1 Method overview. Relations between the drug albuterol and the class beta2-Adrenergic Agonist [EPC], with asserted and inferred drug-class
relations. Note that there is only one direct path from ingredients to pharmacologic classes through the recently added yellow asserted drug-class
relation. In this study, we compare how often inference using the properties, which produces the dashed orange line, recapitulates the solid yellow line.
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reasoner is that it creates a hierarchy of the pharmaco-
logic classes themselves, based on their logical defini-
tions. For example, beta2-Adrenergic Agonist [EPC]
(N0000175779) is inferred to be a subclass of beta-
Adrenergic Agonist [EPC] (N0000175555), because the
definition of beta2-Adrenergic Agonist [EPC] shown
earlier is more specific than that of beta-Adrenergic
Agonist [EPC] ('Pharmaceutical Preparations' and
(has_MoA_FMTSME some 'Adrenergic beta-Agonists
[MoA]')). For this reason, we reclassified both OWL
datasets, although no inferred drug-class relations
were generated in dataset “A”.
Figure 2 provides a screenshot from Protégé of a
pharmacologic class before enrichment and Figure 3
shows its definition after. Before enrichment, the class
beta2-Adrenergic Agonist [EPC] has no sufficient condi-
tions (the section “Equivalent To” is empty) and the
EPCs are not hierarchically related (beta2-Adrenergic
Agonist [EPC] and beta-Adrenergic Agonist [EPC] are at
the same hierarchical level, i.e., part of a flat list of
EPCs). The drug albuterol is asserted to be a member of
the class beta2-Adrenergic Agonist [EPC]. In contrast,
after enrichment (and reclassification), the class beta2-
Adrenergic Agonist [EPC] has acquired sufficient condi-
tions (visible in the section “Equivalent To”) and the
EPCs are now hierarchically related (beta2-Adrenergic
Agonist [EPC] is a subclass of beta-Adrenergic Agonist
[EPC]). The drug albuterol is inferred to be a member of
the class beta2-Adrenergic Agonist [EPC].
Comparing asserted and inferred drug-class relations
We compared asserted (dataset “A”) and inferred (data-
set “I”) drug-class relations from the perspective of drugs
and pharmacologic classes, respectively. In both cases,we issued queries against the OWL datasets (after re-
classification). For each drug, we queried its set of
pharmacologic classes in each dataset and determined
which classes are common to both datasets vs. specific to
one dataset. For example, the drug albuterol
(N0000147099) has the same class in both datasets, beta2-
Adrenergic Agonist [EPC] (N0000175779). In contrast, the
drug hydrochlorothiazide (N0000145995) has an asserted
relation to Thiazide Diuretic [EPC] (N0000175419), but
an inferred relation to Thiazide-like Diuretic [EPC]
(N0000175420). For each pharmacologic class, we queried
its set of drugs in each dataset and determined which
drugs are common to both datasets vs. specific to one
dataset. In order to consider higher-level classes to which
drugs are not direct members, we used the transitive clos-
ure of the hierarchical relation rdfs:subClassOf. As a
consequence, a given class will have as members not only
its direct drugs, but also the members of all its subclasses.
For example, in both the “A” and “I” datasets, the class
beta-Adrenergic Agonist [EPC] has the base ingredient
albuterol as an indirect member through its subclass class
beta2-Adrenergic Agonist [EPC]. Of note, the salt ingre-
dient albuterol sulfate is ignored as a result of the
normalization to RxNorm base ingredients described
earlier.
Implementation
The modifications described above were performed
using an XSL (eXtensible Stylesheet Language) trans-
formation. The resulting OWL file was classified with
HermiT 1.2.2 [8]. Protégé 5.0 was used for visualization
purposes [7]. The OWL file containing the inferences
computed by the reasoner was loaded in the open source
triple store Virtuoso 7.10 [13]. The query language
SPARQL was used for querying drug-class relations
Figure 2 Primitive class Adrenergic Decongestant [EPC]. beta2-Adrenergic Agonist [EPC] appears as a primitive class in the default distribution
of NDF-RT.
Figure 3 Defined class Adrenergic Decongestant [EPC]. The appearance of beta2-Adrenergic Agonist [EPC]in Protégé after augmenting it with
sufficient conditions.
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Asserted and inferred drug-class relations
Drugs
Of the 7,352 drugs (at the ingredient level) in NDF-RT,
3,351 are identifiable as clinically relevant ingredients in
RxNorm. After normalization to base ingredients, 2,247
drugs remain, of which 1,308 have at least one relation
to a pharmacologic class (EPC). As shown in Table 1, all
but 48 drugs (1,260) have asserted drug-class relations
and 1,011 drugs have inferred relations. 963 drugs have
both asserted and inferred relations.
Pharmacologic classes
Of the 553 pharmacologic classes (EPC) in NDF-RT, 463
have relations to drugs, of which all but five (458) have
asserted relations and 340 have inferred relations (as
shown in Table 2). In total, 335 of the 463 classes have
both asserted and inferred relations to drugs.
Drug-class relations
As shown in Figure 4, there are 1,396 asserted and 1,125
inferred direct drug-class relations, of which 825 (59%
and 77%, respectively) are in common. Of the asserted
relations, 571 (41%) could not be inferred, whereas 300
(27%) inferred relations are not present in the asserted
set. Considering the transitive closure of the hierarchical
relation rdfs:subClassOf (for the drug class per-
spective), we obtain 2,211 asserted and 1,513 inferred
drug-class relations, of which 1,332 (40% and 88%, re-
spectively) are in common. Of the asserted relations 879
(40%) could not be inferred, whereas 181 (12%) inferred
relations are not present in the asserted set.
Perspective of drugs
For each drug, we compare the set of (direct) pharmaco-
logic classes in datasets “A” and “I”. The various types of
differences observed between asserted and inferred
drug-class relations are presented in Table 1. The largest
category corresponds to drugs with identical sets of
asserted and inferred drug-class relations (50%). For ex-
ample, the drug imatinib has the same class KinaseTable 1 Drug-class relations (direct), drug perspective
Drugs related to drug classes
Drugs with identical sets of classes for the asserted and inferred drug-class re
Drugs with compatible sets of classes (each class from the asserted is identical t
Drugs with additional drug-class relations in the asserted set only
Drugs with additional drug-class relations in the inferred set only
Drugs with additional drug-class relations in both the asserted and inferred s
Drugs with asserted drug-class relations only (no inferred relations)
Drugs with inferred drug-class relations only (no asserted relations)
Total number of related drugsInhibitor [EPC] in both datasets. Drugs with asserted
drug-class relations, but lacking inferred drug-class rela-
tions represent 23% of the cases. For example, the drug
losartan has the class Angiotensin 2 Receptor Blocker
[EPC] in dataset “A”, but no class in dataset “I”.
Perspective of pharmacologic classes
For each pharmacologic class, we compare the set of
(direct and indirect) drug members in datasets “A” and
“I”. The various types of differences observed between
asserted and inferred drug-class relations are presented
in Table 2. As we observed for drugs, the largest cat-
egory corresponds to EPCs with identical sets of asserted
and inferred drug-class relations (52%). For example, the
class Monoamine Oxidase Inhibitor [EPC] has the same
five drugs in both datasets, including isocarboxazid and
rasagiline. EPCs with asserted drug-class relations, but
lacking inferred drug-class relations also represent
about 27% of the cases. For example, the class Quin-
olone Antibacterial [EPC] has eight drugs in dataset
“A”, including ofloxacin and levofloxacin, but no mem-
bers in dataset “I”.
Discussion
Disparities between asserted and inferred drug-class
relations
Missing inferences
As mentioned in the results, the largest category of dis-
parity is represented by missing inferred drug-class rela-
tions, including cases where there are no inferred
relations at all and cases where inferred relations only
cover part of the asserted relations. Missing inferences
should not be interpreted as an inherent failure of the
OWL reasoner to identify drug-class relations, but ra-
ther as issues with the completeness and quality of class
definitions and drug descriptions (see below for details).
For example, the reason why the drug lurasidone, a drug
indicated for the treatment of schizophrenia, has an
asserted, but not inferred drug-class relation to Atypical
Antipsychotic [EPC] is because the therapeutic intent of
lurasidone (Schizophrenia and Disorders with Psychotic# %
lations 660 50.46







Table 2 Drug-class relations (direct and indirect), class perspective
Drug classes related to drugs # %
Classes with identical sets of drugs for the asserted and inferred drug-class relations 242 52.27
Classes with additional drug-class relations in the asserted set only 55 11.88
Classes with additional drug-class relations in the inferred set only 20 4.32
Classes with additional drug-class relations in both the asserted and inferred set 18 3.89
Classes with asserted drug-class relations only (no inferred relations) 123 26.57
Classes with inferred drug-class relations only (no asserted relations) 5 1.08
Total number of related classes 463 100.00
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no drug property asserted for lurasidone by FDASPL.
Another example is the drug ofloxacin mentioned earl-
ier. In this case, the asserted EPC (Quinolone Antimicro-
bial [EPC]) is not inferred because its definition includes
both may_treat Infectious Diseases and may_prevent
Infectious Diseases, while the drug description only in-
cludes treatment, not prevention (e.g., may_treat 'Klebsi-
ella Infections). Similarly, the description of the drug
ipilimumab is too underspecified to match the definition
of its asserted class, CTLA-4-directed Blocking Antibody
[EPC]. In addition to has_MoA CTLA-4-directed Anti-
body Interactions, which is in the drug description, the
EPC also makes references to the physiologic effect
(has_PE Increased Immunologic Activity and has_PE
Increased T Lymphocyte Activation).
Inferences with no corresponding asserted relations
The number of cases (156 drugs and 43 classes) where
inferred drug-class relations are found when there is no
asserted drug-class relation (or a different asserted drug-
class relation) is interesting as it can help detect poten-
tially missing asserted relations. For example, the drugFigure 4 Comparison of asserted and inferred classes. 59% of
the 1,396 asserted classes are also inferred and 77% of the 1,125 inferred
classes are also asserted.bupropion has a single asserted relation to the structural
class Aminoketone [EPC]. However, it has an inferred re-
lation to Norepinephrine Reuptake Inhibitor [EPC]
(through its mechanism of action, Norepinephrine Up-
take Inhibitors [MoA]). In this case, the set of asserted
relations, which we use as our reference, seems to be in-
complete. Another example is the drug isosorbide, an
anti-angina agent, for which we correctly infer the class
Anti-anginal [EPC], while no asserted EPC is present.
Here again, the reference is incomplete.
Inconsistent drug-class relations due to granularity
differences
Drug-class relations from dataset “A” tend to associate
drugs with more specific classes than in dataset “I”. For
example, the antibiotic amikacin is associated with Ami-
noglycoside Antibacterial [EPC] (through asserted rela-
tions), but with the less specific Aminoglycoside [EPC]
(through inferred relations). The reason here is similar
to what was described earlier for the antibiotic ofloxacin,
i.e., discrepancy between may_treat and may_prevent vs.
only may_treat properties on the side of the EPC and
the drug, respectively. As shown in Table 1, we identified
127 drugs for which the classes in sets “A” and “I” are
hierarchically related. Of these, there are only 4 cases
with an inferred relation to a class that is more specific
than the class involved in the asserted relation.
Specific contribution of the therapeutic intent relations
The DailyMed indexing file provided by the FDA (FDASPL)
only contains drug descriptions in reference to mechanism
of action, physiologic effect and chemical structure, not
therapeutic intent. However, many EPC definitions refer to
may_treat and may_prevent relations. Therefore, no drug-
class relations to these classes can be inferred, because the
corresponding relations are missing from the drug descrip-
tions. Therapeutic intent relations are available for the
drugs as part of the set of legacy relations provided by
NDF-RT (not FDASPL). We used these relations to com-
plement the relations from FDASPL in order to maximize
our chances to infer drug-class relations to the EPCs. We
assessed the specific contribution of the therapeutic intent
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ing a “baseline” without using the therapeutic intent rela-
tions and comparing it to our dataset “I”.
As shown in Table 3, the use of therapeutic intent
relations (column “+DISEASE”) allows us to infer drug-
class relations for an additional 46 drugs compared to
the baseline. There are fewer drugs (82) for which we
only have asserted drug-class relations. Surprisingly,
however, the number of drugs for which the asserted
and inferred classes are the same has not significantly
increased, which indicates that the drug-class relations
inferred with the use of therapeutic intent tends to be
different from the asserted drug-class relations.
For example, the drug citalopram was only associated
with the inferred class Serotonin Reuptake Inhibitor
[EPC] in the baseline (based on its mechanism of
action), which was also its asserted EPC. In addition, it
acquires a relation to Mood Stabilizer [EPC] when using
the therapeutic intent relations, resulting in one add-
itional inferred class compared to the asserted class. This
example illustrates why the use of therapeutic intent re-
lations does not significantly increase the number of
drugs with similar sets of asserted and inferred classes.
Description logics and quality assurance
There is a range of automated ontology quality assur-
ance methods in the literature [14]. The results of thisTable 3 Specific contributions of enhancement step
Drug perspective Baseline + Disease Delta
# drugs with Abs. % Abs. %
Identical sets 657 52.06 660 50.46 3
Compatible sets 122 9.67 127 9.71 5
Additional asserted 66 5.23 68 5.20 2
Additional inferred 18 1.43 73 5.58 55
Additional in both 18 1.43 35 2.68 17
Asserted only 379 30.03 297 22.71 −82
Inferred only 2 0.16 48 3.67 46
Total # drugs 1262 100 1308 100 46
Total # pairs 1569 1696 127
Drug class perspective Baseline + Disease Delta
# classes with Abs. % Abs. %
Identical sets 237 51.19 242 52.27 5
Additional asserted 40 8.64 55 11.88 15
Additional inferred 19 4.10 20 4.32 1
Additional in both 5 1.08 18 3.89 13
Asserted only 157 33.91 123 26.57 −34
Inferred only 5 1.08 5 1.08 0
Total # classes 463 100 463 100 0
Total # pairs 2259 2392 133work highlight the usefulness of DL for that task. Here,
we enriched the logic in NDF-RT to enable us to evalu-
ate the quality and completeness of new, explicitly-
added knowledge. Indeed, such rich logic allows for a
quick evaluation at minimal cost. In this work, we had a
reference against which to compare. However, when a
gold standard is not available, DL reasoners can still
check consistency and satisfiability, automatically detect-
ing logical contradictions that usually indicate an error
exists in the ontology. For instance, Horridge et al. used
reasoning to identify contradictions within ICD-11 [15].
Unfortunately, even considering the benefits of a richly
defined ontology, Noy and colleagues confirmed empir-
ically that most biomedical ontologies do not use rich
semantics but instead rely mostly on simple hierarchical
subsumption relations [16].
Conclusions
As we rely increasingly on ontologies, it is important to
ensure their content is complete and correct. In this
work, we developed a methodology to evaluate the con-
tent of NDF-RT using description logics. We found that
the inferred and asserted relations only matched in
about 50% of the cases. Ideally, the asserted and inferred
drug-class relations should be identical. Our results sug-
gest that there is an opportunity for quality assurance of
NDF-RT content (completeness of the drug descriptions
and quality of the class definitions). This work serves as
an exemplar of how DL can enhance ontology develop-
ment and evaluation and shows ontology developers that
a little semantics can go a long way.
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